References
- Attal M, Harousseau J L, Stoppa A M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
- Weber D M, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142
- Orlowski R Z, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901
- Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
- Richardson P G, Sonneveld P, Schuster M W, et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators: bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
- Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
- Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
- Chanan-Khan A, Miller K C, McCarthy P, et al. VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) is an effective initial therapy with high response rates for patients with treatment naïve multiple myeloma (MM). Blood (ASH) 2004; 104: 3463
- Hussein M A, Elson P, Tso E A. Doxil, Vincristine, Decadron and Thalidomide (DVd-T) for relapsed/refractory mutliple myeloma (RMM), 9th International Workshop on Multiple Myeloma. Nature Publishing Group, Spain 2003; S235, (abstr)
- Mateos M V, Hernández J M, Hernández M T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93: 560–565
- San Miguel J F, Schlag R, Khuageva N K, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917
- Rajkumar S V, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meetting Abstracts 2007; 110: 74, (abstr)
- Richardson P G, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
- Ma M H, Yang H H, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144
- Small G W, Shi Y Y, Edmund N A, Somasundaram S, Moore D T, Orlowski R Z. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 66: 1478–1490
- Mitsiades N, Mitsiades C S, Richardson P G, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380
- Orlowski R Z, Voorhees P M, Garcia R A, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065
- Kraut E H, Crowley J J, Wade J L, et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 589–592
- Miller K C, Padmanabhan S, Dimicelli L, et al. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 2006; 47: 2339–2343
- Chanan-Khan A, Miller K C. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma 2005; 46: 1103–1104